Nuvation Bio Inc (NYSE:NUVB) currently has a daily average trading volume of 3.97M but it saw 18559802 shares traded in last market. With a market cap of 615.88M USD, the company’s current market price of $1.81 came falling about -17.73 while comparing to the previous closing price of $2.20. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.97 and as low as $1.54. In the recent trading on the day, stock has struck highest price mark of $1.8 while lowest mark touched by it was $2.23.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Citizens JMP which initiated the stock as “Mkt Outperform” in its note to investors issued on April 23, 2025, recommending a price target of $6 for it. Jefferies upgraded its recommendation for the stock as a “Buy” from “Hold” on March 27, 2024 while assigning a price target range of $1.40-$10. BTIG Research issued its recommendations for the stock as it upgraded the price target for the stock is $5.
Over the week, NUVB’s stock price is moving -27.02% down while it is -17.35% when we observe its performance for the past one month. Year-to-date it is -31.95% down and over the past year, the stock is showing a downside performance of -37.59%.
The company is expected to be releasing its next quarterly report on 2025-May-06, for which analysts forecasted an EPS of -0.14 while estimate for next year EPS is -0.59. In next quarter, company is expected to be making quarterly sales of $3.1M as analysts are expecting the sales for current fiscal year at $15.53M and seeing the company making $79.38M in sales next year. Moreover, analysts are in estimates of $416.67k for current-quarter revenue.
Currently, Nuvation Bio Inc’s total number of outstanding shares is 338.84M with 19.12% of that held by the insiders while 61.84% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -143.25% and return on equity (ROE) at -119.66%. Stock’s beta reads 1.38. Stock has a price to book (P/B) ratio of 1.47 while price to sale or P/S ratio amounts to 56.19. Its return on asset (ROA) is -109.69% on average.
